132 related articles for article (PubMed ID: 9329560)
1. Pathological aspects of prostate cancer and benign nodular hyperplasia.
Wernert N; Bieroff E; Hügel A
Anticancer Res; 1997; 17(4B):2907-10. PubMed ID: 9329560
[TBL] [Abstract][Full Text] [Related]
2. Role of canine basal cells in prostatic post natal development, induction of hyperplasia, sex hormone-stimulated growth; and the ductal origin of carcinoma.
Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
Prostate; 2001 May; 47(3):149-63. PubMed ID: 11351344
[TBL] [Abstract][Full Text] [Related]
3. Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma.
Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
Prostate; 2001 Aug; 48(3):210-24. PubMed ID: 11494337
[TBL] [Abstract][Full Text] [Related]
4. [Immunohistochemistry of the prostate and prostate carcinomas].
Wernert N
Veroff Pathol; 1991; 135():1-163. PubMed ID: 2038892
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical expression of prostate specific antigen (PSA) in benign and malignant tumors of the prostate.
Dema A; Tudose N
Rom J Morphol Embryol; 1998; 44(1-4):93-100. PubMed ID: 15678849
[TBL] [Abstract][Full Text] [Related]
6. Interferon-gamma and its functional receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: parallelism with c-myc and p53 expression.
Royuela M; de Miguel MP; Ruiz A; Fraile B; Arenas MI; Romo E; Paniagua R
Eur Cytokine Netw; 2000 Mar; 11(1):119-27. PubMed ID: 10705309
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
[TBL] [Abstract][Full Text] [Related]
8. INSL3 in the benign hyperplastic and neoplastic human prostate gland.
Klonisch T; Müller-Huesmann H; Riedel M; Kehlen A; Bialek J; Radestock Y; Holzhausen HJ; Steger K; Ludwig M; Weidner W; Hoang-Vu C; Hombach-Klonisch S
Int J Oncol; 2005 Aug; 27(2):307-15. PubMed ID: 16010410
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate.
Royuela M; Ricote M; Parsons MS; García-Tuñón I; Paniagua R; de Miguel MP
J Pathol; 2004 Jan; 202(1):41-9. PubMed ID: 14694520
[TBL] [Abstract][Full Text] [Related]
10. Expression of cystatins, high molecular weight cytokeratin, and proliferation markers in prostatic adenocarcinoma and hyperplasia.
Mirtti T; Alanen K; Kallajoki M; Rinne A; Söderström KO
Prostate; 2003 Mar; 54(4):290-8. PubMed ID: 12539227
[TBL] [Abstract][Full Text] [Related]
11. Limiting the location of putative human prostate cancer tumor suppressor genes on chromosome 18q.
Yin Z; Babaian RJ; Troncoso P; Strom SS; Spitz MR; Caudell JJ; Stein JD; Kagan J
Oncogene; 2001 Apr; 20(18):2273-80. PubMed ID: 11402322
[TBL] [Abstract][Full Text] [Related]
12. [Various immunohistochemical markers of precancer and variants of prostate cancer].
Romanenko AM; Vorob'eva LR
Arkh Patol; 1995; 57(4):38-41. PubMed ID: 8526754
[TBL] [Abstract][Full Text] [Related]
13. Limiting the diagnosis of atypical small glandular proliferations in needle biopsies of the prostate by the use of immunohistochemistry.
Helpap B; Köllermann J; Oehler U
J Pathol; 2001 Mar; 193(3):350-3. PubMed ID: 11241415
[TBL] [Abstract][Full Text] [Related]
14. Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer.
Schwarzenbach H; Chun FK; Müller I; Seidel C; Urban K; Erbersdobler A; Huland H; Pantel K; Friedrich MG
BJU Int; 2008 Jul; 102(2):253-8. PubMed ID: 18336598
[TBL] [Abstract][Full Text] [Related]
15. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
16. Activator protein 2alpha transcription factor expression is associated with luminal differentiation and is lost in prostate cancer.
Ruiz M; Troncoso P; Bruns C; Bar-Eli M
Clin Cancer Res; 2001 Dec; 7(12):4086-95. PubMed ID: 11751506
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic characterization of the infiltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma.
Hussein MR; Al-Assiri M; Musalam AO
Exp Mol Pathol; 2009 Apr; 86(2):108-13. PubMed ID: 19111537
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate.
Tamboli P; Amin MB; Xu HJ; Linden MD
Mod Pathol; 1998 Mar; 11(3):247-52. PubMed ID: 9521470
[TBL] [Abstract][Full Text] [Related]
19. Histopathology of prostate carcinoma. Diagnosis and differential diagnosis.
Dhom G
Pathol Res Pract; 1985 Jan; 179(3):277-303. PubMed ID: 2580293
[TBL] [Abstract][Full Text] [Related]
20. Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia.
Stamey TA; Warrington JA; Caldwell MC; Chen Z; Fan Z; Mahadevappa M; McNeal JE; Nolley R; Zhang Z
J Urol; 2001 Dec; 166(6):2171-7. PubMed ID: 11696729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]